Johnson & Johnson JNJ
280.41 USD 0.00 (+0.00%)
At closeNov 12, 2026, 9:15 AM EST
283.28 +2.87 +1.02%
Pre-market · Nov 12, 9:15 AM ET
Day range unavailable
193.45 52-week range 283.25
- YTD
- +35.50%
- 1 year
- +44.25%
News
fool.com Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy? Johnson & Johnson is expertly handling a recent major patent cliff. Recent launches should help boost sales growth over the next few years.
benzinga.com Johnson & Johnson Reports Favorable Data For Bipolar Study Johnson & Johnson reports positive Phase 3 CAPLYTA study data, delivering rapid manic symptom relief for adults with bipolar I disorder.
businesswire.com Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541…
benzinga.com Cyclicals Lead Sectors In Wednesday Trading As Defensives Trail Five sectors are higher and six are lower in Wednesday's regular session, with cyclical sectors holding two of the top three positions. Technology sits well clear of the rest, separated from the next…
247wallst.com SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More? One income stream resets every time the Fed moves, while two others depend on a board's vote and a balance sheet. Which payout holds up best over a long retirement, and why might taxes change the…
247wallst.com 3 Legacy Health Care Dividend Stocks That Never Go Out of Style Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to…
zacks.com J&J's Oncology Sales Surge So Far in 2026: What Lies Ahead? J&J's oncology sales surge 16.8% to $22 billion in the first nine months of 2026, fueled by blockbuster drugs and new launches.
247wallst.com Treasuries Now Offer 2.66% Above Inflation. Are Dividend Stocks in Trouble? Real yields hit a level that crushed income stocks once before, and one dividend name is already repeating the old script. Which holdings sat out the damage this time, and what single number could…
247wallst.com $300,000 in Duke Energy, Philip Morris and Johnson & Johnson: Here's What It Pays One utility, one tobacco giant, and one healthcare Dividend King each get $100,000 to see who earns the most. The ranking surprises, and one stock's 64-year raise streak comes with the lowest payout…
reuters.com J&J eyes US nod for Caplyta in bipolar mania after second trial win J&J eyes US nod for Caplyta in bipolar mania after second trial win
businesswire.com Dean Omar Branham Shirley Secures $3,325,000 Verdict Against Johnson & Johnson in Mesothelioma Case DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a $3,325,000 jury verdict against Johnson & Johnson on behalf of the family of Winifred…
benzinga.com Johnson & Johnson's Phase 3 Study Evaluating CAPLYTA Met Its Primary And Key Secondary Endpoints CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studiesTwo positive Phase 3…
prnewswire.com Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studies Two positive Phase 3…
defenseworld.net Johnson & Johnson $JNJ Stock Acquired by AlphaCore Capital LLC AlphaCore Capital LLC increased its stake in shares of Johnson and Johnson (NYSE: JNJ) by 17.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
zacks.com Q3 Earnings Season Winners: 3 Companies Raising Guidance Raised guidance is always a welcome development for investors, reflecting improving business trends and management confidence in the outlook.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com 11 Of 11 Sectors Rise Monday As Growth Leads All 11 sectors are higher in Monday’s regular session, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing…
benzinga.com Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies Johnson & Johnson reported positive Phase 3 ICOTYDE data for psoriatic arthritis and new nipocalimab results at ACR Convergence 2026.
247wallst.com After the Democratic Midterm Sweep: 4 Dividend Stocks Built for Gridlock When Congress locks up, some dividends barely notice. Four blue chips span power, soap, medicine and banking, and one of them already survived a payout collapse that income investors should not…
defenseworld.net Johnson & Johnson $JNJ Holdings Boosted by Candriam S.C.A. Candriam S.C.A. raised its stake in shares of Johnson and Johnson (NYSE: JNJ) by 1.3% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
benzinga.com Reported Saturday, Johnson & Johnson Reports 57% Of Psoriatic Arthritis Patients With Qualifying Skin Involvement On ICOTYDE Achieved Clear Or Almost Clear Skin Versus 14% On Placebo, Alongside 58% ACR20 Response At Week 16 Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an…
benzinga.com Reported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint painPatient insights…
benzinga.com Reported Sunday, Johnson & Johnson Says Pasritamig And JNJ-9401 Achieve 73% PSA Response With No Grade 3 Or Higher Treatment-Related Adverse Events In Phase 1 Prostate Cancer Study, Supporting Outpatient Dosing First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against…
gurufocus.com Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer Johnson and Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerPR NewswireNEW BRUNSW
prnewswire.com Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against…
247wallst.com 3 Dividend Stocks Worth Researching This Weekend A quiet Sunday is a good time to look past the noise and study what actually lands in your account: cash dividends supported by real cash flow.
prnewswire.com Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights…
prnewswire.com Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an…
reuters.com J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial
defenseworld.net Johnson & Johnson $JNJ Shares Sold by Alps Advisors Inc. Alps Advisors Inc. reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 16.0% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The…- defenseworld.net Johnson & Johnson $JNJ Shares Sold by Alps Advisors Inc. Alps Advisors Inc. reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 16.0% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The…
fool.com If Stocks Tumble This Winter, History Says Investors Who Make This 1 Move Come Out Ahead Three words sum up this historically successful investing strategy.
247wallst.com The Average 1-Year CD Pays Just 1.76%. These Dividend Stocks Could Pay More A guaranteed bank rate sounds safe until you weigh what it can't do.
benzinga.com First Therapy for Advanced Head & Neck Cancer in 10 Years: Johnson & Johnson Secures Accelerated FDA Nod Johnson & Johnson wins FDA accelerated approval for RYBREVANT FASPRO to treat recurrent or metastatic head and neck cancer.- benzinga.com Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1First advancement in the…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact…
247wallst.com 3 Dependable Dividend Stocks for a $250,000 Passive Income Strategy Some stocks are worth holding for decades, and they usually have one thing in common: a dividend that went up every year through recessions, rate shocks and bear markets.
247wallst.com Rate Hikes Could Be Coming: History Likes These 4 Dividend Stocks Traders now price an 80% chance the Fed hikes again in December, and Treasuries yield more than every dividend stock on this list. Four income names have a record of thriving through tightening…
defenseworld.net 2,899 Johnson & Johnson $JNJ Shares Sold by Franklin Parlapiano Turner & Welch LLC Franklin Parlapiano Turner and Welch LLC reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 6.7% in the undefined quarter, according to the company in its most recent Form 13F filing…
benzinga.com Jim Cramer Likes This Industrial Stock: ‘It’s Come Down A Great Deal’ Cramer recommends Howmet and J&J, prefers Micron over Western Digital, criticizes Nebius, and favors Lam Research over KLA.
benzinga.com Growth And Cyclical Sectors Lead Monday Trading Seven sectors are higher and four are lower in Monday’s regular session, with growth and cyclical sectors splitting the top of the table. The leaders are separated rather than clustered, with no…
benzinga.com Microsoft Goes Jumbo: $25 Billion Bond Sale in the Works Microsoft plans at least $25B in bonds, its first debt sale since 2017, to fund capital needs as AI-driven spending surges.
benzinga.com Cyclicals Lead Sectors In Wednesday Trading As Real Estate Trails Four sectors are higher and seven are lower in Wednesday’s regular session, with cyclical and defensive sectors split at the top of the table. The leaders are separated rather than clustered, with…- benzinga.com Johnson & Johnson Plans To Hold Enterprise Business Review On Dec. 8 Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leaders will provide a detailed review of…
benzinga.com Nasdaq Gains Over 200 Points As Chip Stocks Rise: Investor Sentiment Improves, Fear & Greed Index Moves to ‘Fear’ Zone U.S. stocks rose Monday as AI shares gained, but CNN’s Fear & Greed Index remained in the Fear zone at 27. Investors await major earnings.
benzinga.com Coca-Cola, Boeing and 3 Stocks to Watch Heading Into Tuesday Stocks in focus: Coca-Cola and Boeing report earnings; Whirlpool cuts guidance after a miss, while Celestica beats estimates and raises outlook.
benzinga.com Mark Cuban Warns CEOs If Your Health Benefits Do Not Actually Help Employees You Are Legally Liable - 'It’s All On You’ Billionaire entrepreneur Mark Cuban says company leaders who treat employee health benefits as someone else's problem may be setting themselves up for a legal reckoning, and he wants them to know it.
benzinga.com Meta Tumbles 6% on AI Spending Fears, 10-Year Yield Falls Below 5%: Stock Market Today Meta's higher AI spending plan drags tech lower as Treasurys rally and the 10-year yield drops below 5%. Gold, silver and Bitcoin fall; oil climbs.
benzinga.com Defensives Lead Sectors In Thursday Trading As Growth Trails Five sectors are higher and six are lower in Thursday’s regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…